CL2017001633A1 - Método de manufactura de proteína. - Google Patents

Método de manufactura de proteína.

Info

Publication number
CL2017001633A1
CL2017001633A1 CL2017001633A CL2017001633A CL2017001633A1 CL 2017001633 A1 CL2017001633 A1 CL 2017001633A1 CL 2017001633 A CL2017001633 A CL 2017001633A CL 2017001633 A CL2017001633 A CL 2017001633A CL 2017001633 A1 CL2017001633 A1 CL 2017001633A1
Authority
CL
Chile
Prior art keywords
protein
manufacturing
protein manufacturing
coupled
industrial scale
Prior art date
Application number
CL2017001633A
Other languages
English (en)
Inventor
Christopher Mark Illidge
Neil Alan Watson
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2017001633A1 publication Critical patent/CL2017001633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J47/00—Ion-exchange processes in general; Apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO NOVEDOSO PARA MANUFACTURAR UNA PROTEÍNA, PARTICULARMENTE DONDE TAL PROTEÍNA ESTÁ SIENDO ACOPLADA CON OTRA MOLÉCULA. LA INVENCIÓN PROPORCIONA ADEMÁS, UN MÉTODO PARA MANUFACTURACIÓN DE PROTEÍNA A ESCALA INDUSTRIAL PARA OBTENER PROTEÍNAS, POR EJEMPLO, PARA PROPÓSITOS TERAPÉUTICOS.</p>
CL2017001633A 2014-12-22 2017-06-20 Método de manufactura de proteína. CL2017001633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14199722 2014-12-22

Publications (1)

Publication Number Publication Date
CL2017001633A1 true CL2017001633A1 (es) 2017-11-24

Family

ID=52282495

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001633A CL2017001633A1 (es) 2014-12-22 2017-06-20 Método de manufactura de proteína.

Country Status (24)

Country Link
US (1) US10626143B2 (es)
EP (1) EP3237433B1 (es)
JP (1) JP6807326B2 (es)
KR (1) KR102537099B1 (es)
CN (1) CN107108691B (es)
AU (1) AU2015371341B2 (es)
BR (1) BR112017013398B1 (es)
CA (1) CA2969981C (es)
CL (1) CL2017001633A1 (es)
CO (1) CO2017006157A2 (es)
DK (1) DK3237433T3 (es)
EA (1) EA039002B1 (es)
ES (1) ES3046837T3 (es)
FI (1) FI3237433T3 (es)
HR (1) HRP20251240T1 (es)
IL (1) IL252712B2 (es)
LT (1) LT3237433T (es)
MX (1) MX381459B (es)
MY (1) MY184085A (es)
PL (1) PL3237433T3 (es)
PT (1) PT3237433T (es)
SG (1) SG11201704841UA (es)
SI (1) SI3237433T1 (es)
WO (1) WO2016102378A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6807327B2 (ja) 2014-12-22 2021-01-06 ユーシービー バイオファルマ エスアールエル タンパク質製造
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN110386978A (zh) * 2018-04-19 2019-10-29 上海多米瑞生物技术有限公司 大肠杆菌周质空间表达的蛋白的提取方法
CN111965356B (zh) * 2019-11-28 2023-09-08 上海荣盛生物药业股份有限公司 巯基还原组合物及荧光微球层析试纸和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5655866A (en) 1995-03-20 1997-08-12 Bellanca; Joseph V. Method of folding a signature for use in bookbinding
AU3305100A (en) * 1999-03-17 2000-10-04 Medical Research Council Method for refolding molecules of polypeptides containing ig domains
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU2005310305A1 (en) * 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
EP1805320B1 (en) * 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
CN101506222B (zh) 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠
US8617531B2 (en) * 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
BR112012022518A2 (pt) 2010-03-17 2020-10-13 Biogenerix Gmbh método para obtenção de g- csf recombinante humano biologicamente ativo
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
CA2815342A1 (en) 2010-10-20 2012-04-26 Medimmune, Llc Methods for processing inclusion bodies
JP6807327B2 (ja) 2014-12-22 2021-01-06 ユーシービー バイオファルマ エスアールエル タンパク質製造
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
AU2015371341A1 (en) 2017-06-29
MX381459B (es) 2025-03-12
JP2018505210A (ja) 2018-02-22
US20170342105A1 (en) 2017-11-30
HRP20251240T1 (hr) 2025-12-05
EA201791423A1 (ru) 2017-10-31
AU2015371341B2 (en) 2021-05-20
SI3237433T1 (sl) 2025-11-28
IL252712B1 (en) 2023-12-01
CA2969981C (en) 2024-06-25
JP6807326B2 (ja) 2021-01-06
CN107108691A (zh) 2017-08-29
IL252712B2 (en) 2024-04-01
EP3237433B1 (en) 2025-07-30
LT3237433T (lt) 2025-11-10
IL252712A0 (en) 2017-08-31
ES3046837T3 (en) 2025-12-02
PT3237433T (pt) 2025-10-21
KR20170090510A (ko) 2017-08-07
SG11201704841UA (en) 2017-07-28
EA039002B1 (ru) 2021-11-19
CN107108691B (zh) 2021-06-29
BR112017013398B1 (pt) 2023-12-05
WO2016102378A1 (en) 2016-06-30
PL3237433T3 (pl) 2025-12-08
DK3237433T3 (da) 2025-10-20
BR112017013398A2 (pt) 2018-03-06
CA2969981A1 (en) 2016-06-30
CO2017006157A2 (es) 2017-09-20
MY184085A (en) 2021-03-17
KR102537099B1 (ko) 2023-05-25
US10626143B2 (en) 2020-04-21
FI3237433T3 (fi) 2025-10-14
MX2017007670A (es) 2017-10-27
EP3237433A1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
DK3292137T3 (da) Proteiner specifikke for cd137
CL2017001584A1 (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
MX375524B (es) Anticuerpos anti-axl.
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
DK3708668T3 (da) Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
HUE059158T2 (hu) Eljárás pridopidin elõállítására
HUE071193T2 (hu) Sejtek transzfekció utáni korai izolálása (EPIC) biologikumok elõállításához
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
DK3453721T3 (da) Process of manufacture of annexin v
LT3237432T (lt) Baltymo gamyba
BR112016019390A2 (pt) proteínas de fusão uti
MX382864B (es) Formulaciones de anticuerpos cristalinos.
CO2018010286A2 (es) Método para la purificación de proteínas
CL2017002255A1 (es) Procesos para preparar fluorocetólidos.
MX2017007670A (es) Metodo de manufactura de proteina.
BR112017002139A2 (pt) ?método para preparar um composto?
BR112016019246A2 (pt) processo paraa fabricação de hidroclorofluoro-olefinas
HUE064397T2 (hu) Készítmények glükózszirupok elõállítására
CL2017001383A1 (es) Proceso para la fabricación de anhídrido carboxílico
MX382659B (es) Proceso para la preparación de derivados de tiazol.
MX382631B (es) Proceso para la preparacion de derivados dihidroisoxazol.